Zhitong Finance App News, Goli Pharmaceutical-B (01672.HK) issued an announcement. After recently receiving approval from the US Food and Drug Administration (FDA) for clinical trials (IND) of new drugs, it has initiated a US phase I study on ASC36 oral tablets (oral insulin receptor agonist polypeptides) for the treatment of obesity.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.